Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

Income Statement

Follow revenue through to earnings.

Revenue

$116.59M

FY 2025 · Annual

+10.2% YoY

Operating Income

$11.49M

FY 2025 · Annual

-28.9% YoY

Net Income

$5.03M

FY 2025 · Annual

-58.4% YoY

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.34M102.29M113.45M105.76M116.59M
Cost of Revenue7.67M4.79M4.64M3.88M5.42M
Gross Profit(332K)97.5M108.81M101.87M111.17M
Gross Margin-4.5%95.3%95.9%96.3%95.4%
Research & Development64.57M16.69M13.78M12.02M13.7M
Selling, General & Admin18.82M71.61M75.82M73.62M85.98M
Operating Expenses83.39M88.29M176.04M85.71M99.68M
Depreciation & Amortization290K1.13M1.11M1.59M2.52M
EBITDA(87.64M)10.54M20.33M17.82M16.96M
EBITDA Margin-1194.4%10.3%17.9%16.8%14.5%
Operating Income(83.73M)9.2M(67.23M)16.16M11.49M
Operating Margin-1141.0%9.0%-59.3%15.3%9.9%
Interest Income39K726K1.04M1.55M1.75M
Interest Expense00000
Other Income / Expenses(4.21M)209K(9.74M)7.06M2.95M
Income Before Tax(87.93M)9.41M(76.97M)23.22M14.44M
Pre-Tax Margin-1198.3%9.2%-67.8%22.0%12.4%
Income Tax Expense05.1M8.52M5.32M4.56M
Net Income(87.93M)2.3M(92.93M)12.09M5.03M
Net Margin-1198.3%2.3%-81.9%11.4%4.3%
EPS (Basic)(2.87)0.03(1.41)0.140.06
EPS (Diluted)(2.87)0.03(1.41)0.050.02
Weighted Avg Shares30.64M76.74M65.83M85.09M89.34M
Weighted Avg Shares (Diluted)30.64M75.69M65.83M102.29M103.18M

GYRE Earnings Waterfall · TTM

NASDAQ:GYRE · Revenue to Net Income

Key Ratios

EPS$-0.08
Gross Margin95.1%
Net Margin-7.4%
P/E Ratio76.2
P/S Ratio22.9

Analysis

$117.0M of revenue converted into -$6.3M of net income for the selected period. Gross margin is 95.1% and net margin is -7.4%, showing how much revenue survives after costs and taxes. EPS is $-0.08, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 5, 2026
8-KCurrent reportOct 22, 2026
8-KCurrent reportSep 1, 2026
S-8S-8 filingAug 27, 2026

How much revenue does GYRE generate?

Gyre Therapeutics, Inc. (GYRE) reported $116.59M of revenue in fiscal 2025.

Is GYRE profitable?

Gyre Therapeutics, Inc. (GYRE) reported $5.03M of net income, with a net margin of 4.3%.